Price (delayed)
$37.17
Market cap
$2.05B
P/E Ratio
34.42
Dividend/share
N/A
EPS
$1.08
Enterprise value
$2.05B
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for
There are no recent dividends present for SUPN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.